New Launch21 Mar 2026, 09:31 am
Zydus Lifesciences Launches Innovative, Reusable Semaglutide Injection Pen in India
AI Summary
Zydus Lifesciences Limited has launched Semaglutide Injection under the brand names – SEMAGLYNTM, MASHEMATM and ALTERMETM, upon patent expiry in India. The novel pen device, available for patients in a prefilled cartridge, is administered using a patient-friendly reusable pen. The drug will be used for treating both Type 2 Diabetes Mellitus and Obesity indications. The reusable multi-dose pen device is expected to improve adherence, enhance convenience, and lower the overall therapy cost. The average monthly cost of the treatment is approximately Rs. 2,200.
Key Highlights
- Zydus launches Semaglutide Injection in India under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
- The novel pen device is reusable, innovative, and patient-friendly with a prefilled cartridge.
- The drug is approved by the Drug Controller General of India (DCGI) for treating Type 2 Diabetes Mellitus and Obesity indications.
- The reusable multi-dose pen device is expected to improve adherence, enhance convenience, and lower the overall therapy cost.
- The average monthly cost of the treatment is approximately Rs. 2,200.